Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function

Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5.

Authors

F Perner¹, T M Schnöder¹, S Ranjan², D Wolleschak¹, C Ebert¹, M C Pils³, S Frey¹, A Polanetzki¹, C Fahldieck¹, U Schönborn¹, B Schraven^{4

5}, B Isermann², T Fischer¹, F H Heidel¹

Affiliations

¹ Department of Hematology and Oncology, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
² Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
³ Mouse-Pathology, Animal Experimental Unit, Helmholtz-Center for Infection Research (HZI), Braunschweig, Germany.
⁴ Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany.
⁵ Department of Immune Control, Helmholtz-Center for Infection Research (HZI), Braunschweig, Germany.

PMID: 26242463
DOI: 10.1038/leu.2015.218

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Benzamides / pharmacology
Cells, Cultured
Disease Models, Animal
Graft vs Host Disease / drug therapy
Graft vs Host Disease / immunology*
Graft vs Host Disease / metabolism
Graft vs Host Disease / pathology
Humans
Janus Kinases / antagonists & inhibitors*
Mice
Mice, Inbred BALB C
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / immunology*
Myeloproliferative Disorders / metabolism
Myeloproliferative Disorders / pathology
Protein Kinase Inhibitors / pharmacology*
Pyrimidines / pharmacology
T-Lymphocytes / drug effects
T-Lymphocytes / immunology*
T-Lymphocytes / pathology

Substances

Benzamides
Protein Kinase Inhibitors
Pyrimidines
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Janus Kinases